Health Catalyst, Inc. filings document operating results, material-event reporting, and governance changes for a Nasdaq-listed healthcare data and analytics company. Recent Form 8-K disclosures include quarterly and annual financial results, preliminary unaudited financial updates, and press-release exhibits furnished under results-of-operations items.
The company’s filings also cover board appointments, executive transitions, compensatory arrangements, transition and separation agreements, executive severance-plan references, workforce-reduction disclosures, and related governance matters. These records provide formal disclosure around Health Catalyst’s management structure, financial condition, and material corporate events.
Health Catalyst, Inc. (HCAT) reported that Chief Financial Officer Jason Alger had 17,973 shares of common stock disposed of on September 1, 2026 to cover tax withholding obligations tied to vesting Restricted Stock Units. The transaction, at $1.7036 per share, was a mandated sell-to-cover and not a discretionary trade, leaving him with 704,867 shares held directly.
Health Catalyst, Inc. (HCAT) director and CEO Albert Benjamin reported a Form 4 transaction related to equity compensation. On September 1, 2026, he disposed of 321 shares of common stock at $1.7036 per share to cover tax withholding obligations arising from vesting of Restricted Stock Units, a sale mandated under the company’s equity incentive plans rather than a discretionary trade. Following this tax-withholding transaction, he directly holds 1,423,650 shares of common stock, and no Rule 10b5-1 trading plan is reported.
Health Catalyst, Inc. (HCAT) reported that its General Counsel, Benjamin Landry, had 13,167 shares of common stock disposed of on September 1, 2026 at $1.7036 per share to satisfy tax withholding obligations from vesting Restricted Stock Units. The filing states this mandated "sell to cover" transaction was not a discretionary trade and left him with 351,372 shares held directly.
Health Catalyst, Inc. (HCAT) officer Benjamin Albert filed a Form 144 indicating a proposed sale of 321 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC on or about 09/01/2026 under Rule 144. The securities are restricted stock originally acquired as compensation. Over the prior three months, Albert reported Rule 144 sales of restricted stock on 06/01/2026 and 06/10/2026.
Health Catalyst, Inc. (HCAT) has a Form 144 filing indicating that officer Jason Alger plans to sell up to 17,973 shares of common stock of Health Catalyst through Morgan Stanley Smith Barney LLC under Rule 144, with an intended sale date of September 1, 2026.
The shares are described as Restricted Stock acquired as compensation75,256,381 as of September 1, 2026; this is a baseline figure, not the amount being sold. Over the prior three months, Alger reported selling 18,804 restricted shares for an aggregate value of $25,765.24.
Health Catalyst, Inc. (HCAT) has a notice of proposed insider sales filed under Rule 144 for shares held by officer Benjamin Landry. The filing states that up to 13,167 shares of common stock may be sold through broker Morgan Stanley Smith Barney LLC, with an aggregate market value reference of $22,431.30 and a stated trading market of NASDAQ. The securities to be sold are described as restricted stock acquired as compensation, with a proposed sale date of September 1, 2026. The filing also lists prior sales over the past three months totaling 13,779 shares of restricted stock for $18,879.99.
Health Catalyst, Inc. received an updated ownership report from a group of investment entities associated with Clint D. Coghill. As of June 30, 2026, Stoney Lonesome HF LP directly held 6,772,260 common shares and Drake Helix Holdings, LLC directly held 320,438 shares. Through control relationships, CDC Financial, Inc. and Clint D. Coghill may each be deemed to beneficially own 7,095,498 shares in total, representing approximately 9.6% of the 73,894,020 shares outstanding as of May 22, 2026. The reporting persons state that they may be deemed beneficial owners via their roles but specifically disclaim beneficial ownership of shares they do not directly own.
Health Catalyst, Inc. reported second-quarter and six-month 2026 results showing lower revenue and a large non-cash goodwill charge. Total revenue was $70,487 thousand for the quarter and $141,243 thousand for the first half, down from $80,721 thousand and $160,134 thousand a year earlier, with both technology subscriptions and professional services declining.
Loss from operations was $36,480 thousand in the quarter and $142,957 thousand year-to-date. Net loss reached $40,537 thousand for the quarter and $151,563 thousand, or $2.07 per share, for the first half, largely driven by $122,548 thousand of goodwill impairment in the technology reporting unit. Goodwill fell to $11,101 thousand and stockholders’ equity declined to $100,827 thousand.
Liquidity remained solid, with cash and cash equivalents of $60,589 thousand, short-term investments of $42,850 thousand, and positive operating cash flow of $18,786 thousand in the first half. A term loan of $159,947 thousand remains outstanding. The company agreed to sell its Vitalware business for a base purchase price of $147 million, classifying $91,424 thousand of assets and $12,133 thousand of liabilities as held for sale.
Health Catalyst, Inc. completed the divestiture of all equity interests in its Vitalware business to Med-Metrix, receiving an aggregate base purchase price of $147 million. Net proceeds plus cash on hand were used to voluntarily repay in full its credit facility, including $122.8 million of initial term loan principal, $37.1 million of delayed draw principal, a prepayment premium and accrued interest, terminating the facility and releasing all liens. The company estimates this will eliminate about $19 million of annual interest expense on a GAAP basis.
For the quarter ended June 30, 2026, total revenue was $70.5 million, down 13% year over year, with gross margin improving to 40%. Net loss was $40.5 million, including a $27.0 million goodwill impairment, while Adjusted EBITDA rose 6% to $9.9 million. As of June 30, 2026, cash and cash equivalents were $60.6 million and short-term investments were $42.9 million. The company generated $18.8 million of operating cash flow in the first half of 2026. Guidance for 2026 calls for total revenue of $246–$249 million and Adjusted EBITDA of $18–$18.5 million.
BlackRock, Inc. reports its beneficial ownership of common stock of Health Catalyst, Inc. on an amended Schedule 13G. BlackRock reports beneficial ownership of 1,128,517 shares of common stock, representing 1.5% of the outstanding class.
BlackRock reports sole voting power and sole dispositive power over all 1,128,517 shares, with no shared voting or dispositive power. Various underlying clients or persons have rights to dividends or sale proceeds, but no single person is reported to hold more than five percent of Health Catalyst’s outstanding common shares. The filing indicates ownership of five percent or less of the class.